Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems—A chemical biology approach for thrombosis-related side effects

International Journal of Molecular Sciences

Volumn 16, Issue 1, 2015, Pages 1008-1029

  Berg, Ellen L ^a   Polokoff, Mark A ^a   O’mahony, Alison ^a   Nguyen, Dat ^a   Li, Xitong ^a  

^a DiscoveRx Corporation   (United States)

Author keywords

Aryl hydrocarbon receptor; Bacterial sensing; Cholesterol; Endothelial cells; Hypoxia; Inflammation; Nutrient sensing; Pathway; Primary human cells; Thrombosis; Tissue factor; Toxicity

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ANTAGONIST; HISTAMINE H1 RECEPTOR AGONIST; HLA DR ANTIGEN; INTERLEUKIN 8; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; AROMATIC HYDROCARBON RECEPTOR; BIOLOGICAL MARKER; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ORGANIC COMPOUND; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR TRAP; HUMAN; HUMAN CELL; HYPOXIA; MICROARRAY ANALYSIS; MICROTITER PLATE ASSAY; PHENOTYPE; PROTEIN EXPRESSION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; THROMBOSIS; TOXICITY; VASCULITIS; AGONISTS; ANTAGONISTS AND INHIBITORS; AUTOPHAGY; BIOLOGICAL MODEL; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; METABOLISM;

BACTERIA (MICROORGANISMS);

AUTOPHAGY; BIOMARKERS; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MODELS, BIOLOGICAL; ORGANIC CHEMICALS; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, ESTROGEN; THROMBOPLASTIN; THROMBOSIS; TOR SERINE-THREONINE KINASES;

EID: 84920506777     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16011008     Document Type: Article

References (70)

1. Kleinstreuer, N.C.; Yang, J.; Berg, E.L.; Knudsen, T.B.; Richard, A.M.; Martin, M.T.; Reif, D.M.; Judson, R.S.; Polokoff, M.; Dix, D.J. et al. Phenotypic screening of the toxcast chemical library to classify toxic and therapeutic mechanisms. Nat. Biotechnol. 2014, 32, 583–591.
2. Owens, A.P.; Mackman, N. Tissue factor and thrombosis: The clot starts here. Thromb. Haemost. 2010, 104, 432–439.
3. Mackman, N. The many faces of tissue factor. J. Thromb. Haemost. 2009, 7, 136–139.
4. Williams, J.C.; Mackman, N. Tissue factor in health and disease. Front. Biosci. 2012, 4, 358–372.
5. McElroy, A.K.; Erickson, B.R.; Flietstra, T.D.; Rollin, P.E.; Nichol, S.T.; Towner, J.S.; Spiropoulou, C.F. Ebola hemorrhagic fever: Novel biomarker correlates of clinical outcome. J. Infect. Dis. 2014, 210, 558–566.
6. Barua, R.S.; Ambrose, J.A. Mechanisms of coronary thrombosis in cigarette smoke exposure. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 1460–1467.
7. Lipton, A.; Harvey, H.A.; Hamilton, R.W. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat. Rep. 1984, 68, 887–889.
8. Cummings, S.R.; Eckert, S.; Krueger, K.A.; Grady, D.; Powles, T.J.; Cauley, J.A.; Norton, L.; Nickelsen, T.; Bjarnason, N.H.; Morrow, M. et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the more randomized trial. Multiple outcomes of raloxifene evaluation. J. Am. Med. Assoc. 1999, 281, 2189–2197.
9. Owens, A.P., 3rd; Mackman, N. Role of tissue factor in atherothrombosis. Curr. Atheroscler. Rep. 2012, 14, 394–401.
10. Camici, G.G.; Steffel, J.; Amanovic, I.; Breitenstein, A.; Baldinger, J.; Keller, S.; Luscher, T.F.; Tanner, F.C. Rapamycin promotes arterial thrombosis in vivo: Implications for everolimus and zotarolimus eluting stents. Eur. Heart J. 2010, 31, 236–242.
11. Judson, R.; Kavlock, R.; Martin, M.; Reif, D.; Houck, K.; Knudsen, T.; Richard, A.; Tice, R.R.; Whelan, M.; Xia, M. et al. Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. Altex 2013, 30, 51–56.
12. Lounkine, E.; Keiser, M.J.; Whitebread, S.; Mikhailov, D.; Hamon, J.; Jenkins, J.L.; Lavan, P.; Weber, E.; Doak, A.K.; Cote, S. et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012, 486, 361–367.
13. Ankley, G.T.; Bennett, R.S.; Erickson, R.J.; Hoff, D.J.; Hornung, M.W.; Johnson, R.D.; Mount, D.R.; Nichols, J.W.; Russom, C.L.; Schmieder, P.K. et al. Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 2010, 29, 730–741.
14. Landesmann, B.; Mennecozzi, M.; Berggren, E.; Whelan, M. Adverse outcome pathway-based screening strategies for an animal-free safety assessment of chemicals. Altern. Lab. Anim. ATLA 2013, 41, 461–471.
15. Vinken, M. The adverse outcome pathway concept: A pragmatic tool in toxicology. Toxicology 2013, 312, 158–165.
16. Berg, E.L.; Kunkel, E.J.; Hytopoulos, E.; Plavec, I. Characterization of compound mechanisms and secondary activities by biomap analysis. J. Pharmacol. Toxicol. Methods 2006, 53, 67–74.
17. Berg, E.L.; Yang, J.; Melrose, J.; Nguyen, D.; Privat, S.; Rosler, E.; Kunkel, E.J.; Ekins, S. Chemical target and pathway toxicity mechanisms defined in primary human cell systems. J. Pharmacol. Toxicol. Methods 2010, 61, 3–15.
18. Kunkel, E.J.; Dea, M.; Ebens, A.; Hytopoulos, E.; Melrose, J.; Nguyen, D.; Ota, K.S.; Plavec, I.; Wang, Y.; Watson, S.R. et al. An integrative biology approach for analysis of drug action in models of human vascular inflammation. FASEB J. 2004, 18, 1279–1281.
19. Kunkel, E.J.; Plavec, I.; Nguyen, D.; Melrose, J.; Rosler, E.S.; Kao, L.T.; Wang, Y.; Hytopoulos, E.; Bishop, A.C.; Bateman, R. et al. Rapid structure-activity and selectivity analysis of kinase inhibitors by biomap analysis in complex human primary cell-based models. Assay Drug Dev. Technol. 2004, 2, 431–441.
20. Houck, K.A.; Dix, D.J.; Judson, R.S.; Kavlock, R.J.; Yang, J.; Berg, E.L. Profiling bioactivity of the toxcast chemical library using biomap primary human cell systems. J. Biomol. Screen. 2009, 14, 1054–1066.
21. Berg, E.L.; Yang, J.; Polokoff, M.A. Building predictive models for mechanism-of-action classification from phenotypic assay data sets. J. Biomol. Screen. 2013, 18, 1260–1269.
22. Garrison, J.L.; Kunkel, E.J.; Hegde, R.S.; Taunton, J. A substrate-specific inhibitor of protein translocation into the endoplasmic reticulum. Nature 2005, 436, 285–289.
23. Williams, O.; Houseman, B.T.; Kunkel, E.J.; Aizenstein, B.; Hoffman, R.; Knight, Z.A.; Shokat, K.M. Discovery of dual inhibitors of the immune cell PI3Ks p110δ and p110γ: A prototype for new anti-inflammatory drugs. Chem. Biol. 2010, 17, 123–134.
24. Bergamini, G.; Bell, K.; Shimamura, S.; Werner, T.; Cansfield, A.; Muller, K.; Perrin, J.; Rau, C.; Ellard, K.; Hopf, C. et al. A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation. Nat. Chem. Biol. 2012, 8, 576–582.
25. Xu, D.; Kim, Y.; Postelnek, J.; Vu, M.D.; Hu, D.Q.; Liao, C.; Bradshaw, M.; Hsu, J.; Zhang, J.; Pashine, A. et al. Rn486, a selective brutonߣs tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J. Pharmacol. Exp. Ther. 2012, 341, 90–103.
26. Parry, G.C.; Mackman, N. Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 1995, 15, 612–621.
27. Fuste, B.; Serradell, M.; Escolar, G.; Cases, A.; Mazzara, R.; Castillo, R.; Ordinas, A.; Diaz-Ricart, M. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb. Haemost. 2002, 88, 678–685.
28. Bode, M.; Mackman, N. Regulation of tissue factor gene expression in monocytes and endothelial cells: Thromboxane a as a new player. Vasc. Pharmacol. 2014, 62, 57–62.
29. Gondouin, B.; Cerini, C.; Dou, L.; Sallee, M.; Duval-Sabatier, A.; Pletinck, A.; Calaf, R.; Lacroix, R.; Jourde-Chiche, N.; Poitevin, S. et al. Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney Int. 2013, 84, 733–744.
30. Nishibe, T.; Parry, G.; Ishida, A.; Aziz, S.; Murray, J.; Patel, Y.; Rahman, S.; Strand, K.; Saito, K.; Saito, Y. et al. Oncostatin M promotes biphasic tissue factor expression in smooth muscle cells: Evidence for Erk-1/2 activation. Blood 2001, 97, 692–699.
31. Ryter, S.W.; Choi, A.M. Autophagy: An integral component of the mammalian stress response. J. Biochem. Pharmacol. Res. 2013, 1, 176–188.
32. Ni, H.M.; Williams, J.A.; Yang, H.; Shi, Y.H.; Fan, J.; Ding, W.X. Targeting autophagy for the treatment of liver diseases. Pharmacol. Res. 2012, 66, 463–474.
33. Kambas, K.; Mitroulis, I.; Apostolidou, E.; Girod, A.; Chrysanthopoulou, A.; Pneumatikos, I.; Skendros, P.; Kourtzelis, I.; Koffa, M.; Kotsianidis, I. et al. Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis. PLoS One 2012, 7, e45427.
34. Dunlop, E.A.; Tee, A.R. mTOR and autophagy: A dynamic relationship governed by nutrients and energy. Semin. Cell Dev. Biol. 2014, 36, 121–129.
35. Yang, Z.J.; Chee, C.E.; Huang, S.; Sinicrope, F.A. The role of autophagy in cancer: Therapeutic implications. Mol. Cancer Ther. 2011, 10, 1533–1541.
36. Jiang, P.; Lan, Y.; Luo, J.; Ren, Y.L.; Liu, D.G.; Pang, J.X.; Liu, J.; Li, J.; Wang, C.; Cai, J.P. Rapamycin promoted thrombosis and platelet adhesion to endothelial cells by inducing membrane remodeling. BMC Cell Biol. 2014, 15, doi:10.1186/1471-2121-15-7.
37. Chen, G.; Zhang, W.; Li, Y.P.; Ren, J.G.; Xu, N.; Liu, H.; Wang, F.Q.; Sun, Z.J.; Jia, J.; Zhao, Y.F. Hypoxia-induced autophagy in endothelial cells: A double-edged sword in the progression of infantile haemangioma? Cardiovasc. Res. 2013, 98, 437–448.
38. Gallo, S.; Gatti, S.; Sala, V.; Albano, R.; Costelli, P.; Casanova, E.; Comoglio, P.M.; Crepaldi, T. Agonist antibodies activating the met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy. Cell Death Dis. 2014, 5, doi:10.1038/cddis.2014.155.
39. Katiyar, S.; Liu, E.; Knutzen, C.A.; Lang, E.S.; Lombardo, C.R.; Sankar, S.; Toth, J.I.; Petroski, M.D.; Ronai, Z.; Chiang, G.G. Redd1, an inhibitor of mtor signalling, is regulated by the cul4a-ddb1 ubiquitin ligase. EMBO Rep. 2009, 10, 866–872.
40. Podechard, N.; le Ferrec, E.; Rebillard, A.; Fardel, O.; Lecureur, V. Npc1 repression contributes to lipid accumulation in human macrophages exposed to environmental aryl hydrocarbons. Cardiovasc. Res. 2009, 82, 361–370.
41. Xu, J.; Dang, Y.; Ren, Y.R.; Liu, J.O. Cholesterol trafficking is required for mtor activation in endothelial cells. Proc. Natl. Acad. Sci. USA 2010, 107, 4764–4769.
42. Sarkar, S.; Carroll, B.; Buganim, Y.; Maetzel, D.; Ng, A.H.; Cassady, J.P.; Cohen, M.A.; Chakraborty, S.; Wang, H.; Spooner, E. et al. Impaired autophagy in the lipid-storage disorder niemann-pick type c1 disease. Cell Rep. 2013, 5, 1302–1315.
43. Welch, C.L.; Sun, Y.; Arey, B.J.; Lemaitre, V.; Sharma, N.; Ishibashi, M.; Sayers, S.; Li, R.; Gorelik, A.; Pleskac, N. et al. Spontaneous atherothrombosis and medial degradation in Apoe-/-, Npc1-/- mice. Circulation 2007, 116, 2444–2452.
44. Travassos, L.H.; Carneiro, L.A.; Ramjeet, M.; Hussey, S.; Kim, Y.G.; Magalhaes, J.G.; Yuan, L.; Soares, F.; Chea, E.; le Bourhis, L. et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat. Immunol. 2010, 11, 55–62.
45. Madaro, L.; Marrocco, V.; Carnio, S.; Sandri, M.; Bouche, M. Intracellular signaling in Er stress-induced autophagy in skeletal muscle cells. FASEB J. 2013, 27, 1990–2000.
46. Page, E.L.; Robitaille, G.A.; Pouyssegur, J.; Richard, D.E. Induction of hypoxia-inducible factor-1α by transcriptional and translational mechanisms. J. Biol. Chem. 2002, 277, 48403–48409.
47. Steffel, J.; Akhmedov, A.; Greutert, H.; Luscher, T.F.; Tanner, F.C. Histamine induces tissue factor expression: Implications for acute coronary syndromes. Circulation 2005, 112, 341–349.
48. Stobbe-Maicherski, N.; Wolff, S.; Wolff, C.; Abel, J.; Sydlik, U.; Frauenstein, K.; Haarmann-Stemmann, T. The interleukin-6-type cytokine oncostatin m induces aryl hydrocarbon receptor expression in a STAT3-dependent manner in human HEPG2 hepatoma cells. FEBS J. 2013, 280, 6681–6690.
49. Vollmer, S.; Kappler, V.; Kaczor, J.; Flugel, D.; Rolvering, C.; Kato, N.; Kietzmann, T.; Behrmann, I.; Haan, C. Hypoxia-inducible factor 1α is up-regulated by oncostatin m and participates in oncostatin m signaling. Hepatology 2009, 50, 253–260.
50. Sinha, R.A.; You, S.H.; Zhou, J.; Siddique, M.M.; Bay, B.H.; Zhu, X.; Privalsky, M.L.; Cheng, S.Y.; Stevens, R.D.; Summers, S.A. et al. Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. J. Clin. Investig. 2012, 122, 2428–2438.
51. Debeij, J.; Dekkers, O.M.; Asvold, B.O.; Christiansen, S.C.; Naess, I.A.; Hammerstrom, J.; Rosendaal, F.R.; Cannegieter, S.C. Increased levels of free thyroxine and risk of venous thrombosis in a large population-based prospective study. J. Thromb. Haemost. 2012, 10, 1539–1546.
52. Podrez, E.A.; Poliakov, E.; Shen, Z.; Zhang, R.; Deng, Y.; Sun, M.; Finton, P.J.; Shan, L.; Febbraio, M.; Hajjar, D.P. et al. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor cd36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 2002, 277, 38517–38523.
53. Hutter, R.; Speidl, W.S.; Valdiviezo, C.; Sauter, B.; Corti, R.; Fuster, V.; Badimon, J.J. Macrophages transmit potent proangiogenic effects of oxldl in vitro and in vivo involving HIF-1α activation: A novel aspect of angiogenesis in atherosclerosis. J. Cardiovasc. Transl. Res. 2013, 6, 558–569.
54. Zhang, Y.L.; Cao, Y.J.; Zhang, X.; Liu, H.H.; Tong, T.; Xiao, G.D.; Yang, Y.P.; Liu, C.F. The autophagy-lysosome pathway: A novel mechanism involved in the processing of oxidized LDL in human vascular endothelial cells. Biochem. Biophys. Res. Commun. 2010, 394, 377–382.
55. Ding, W.X.; Manley, S.; Ni, H.M. The emerging role of autophagy in alcoholic liver disease. Exp. Biol. Med. 2011, 236, 546–556.
56. Thomes, P.G.; Ehlers, R.A.; Trambly, C.S.; Clemens, D.L.; Fox, H.S.; Tuma, D.J.; Donohue, T.M. Multilevel regulation of autophagosome content by ethanol oxidation in HEPG2 cells. Autophagy 2013, 9, 63–73.
57. Mestas, J.; Hughes, C.C.W. Of mice and not men: Differences between mouse and human immunology. J. Immunol. 2004, 172, 2731–2738.
58. Berg, E.L.; Kunkel, E.J.; Hytopoulos, E. Biological complexity and drug discovery: A practical systems biology approach. Syst. Biol. 2005, 152, 201–206.
59. Aberg, M.; Siegbahn, A. Tissue factor non-coagulant signaling—Molecular mechanisms and biological consequences with a focus on cell migration and apoptosis. J. Thromb. Haemost. 2013, 11, 817–825.
60. Schaffner, F.; Ruf, W. Tissue factor and PAR2 signaling in the tumor microenvironment. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 1999–2004.
61. Lupu, C.; Westmuckett, A.D.; Peer, G.; Ivanciu, L.; Zhu, H.; Taylor, F.B., Jr.; Lupu, F. Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of escherichia coli sepsis. Am. J. Pathol. 2005, 167, 1161–1172.
62. Song, D.; Ye, X.; Xu, H.; Liu, S.F. Activation of endothelial intrinsic NF-κb pathway impairs protein C anticoagulation mechanism and promotes coagulation in endotoxemic mice. Blood 2009, 114, 2521–2529.
63. Ahamed, J.; Ruf, W. Protease-activated receptor 2-dependent phosphorylation of the tissue factor cytoplasmic domain. J. Biol. Chem. 2004, 279, 23038–23044.
64. Rao, L.V.; Pendurthi, U.R. Regulation of tissue factor coagulant activity on cell surfaces. J. Thromb. Haemost. 2012, 10, 2242–2253.
65. Spronk, H.M.; ten Cate, H.; van der Meijden, P.E. Differential roles of tissue factor and phosphatidylserine in activation of coagulation. Thromb. Res. 2014, 133, S54–S56.
66. Attene-Ramos, M.S.; Miller, N.; Huang, R.; Michael, S.; Itkin, M.; Kavlock, R.J.; Austin, C.P.; Shinn, P.; Simeonov, A.; Tice, R.R. et al. The Tox21 robotic platform for the assessment of environmental chemicals—from vision to reality. Drug Discov. Today 2013, 18, 716–723.
67. Tice, R.R.; Austin, C.P.; Kavlock, R.J.; Bucher, J.R. Improving the human hazard characterization of chemicals: A Tox21 update. Environ. Health Perspect. 2013, 121, 756–765.
68. Rotroff, D.M.; Martin, M.T.; Dix, D.J.; Filer, D.L.; Houck, K.A.; Knudsen, T.B.; Sipes, N.S.; Reif, D.M.; Xia, M.; Huang, R. et al. Predictive endocrine testing in the 21st century using in vitro assays of estrogen receptor signaling responses. Environ. Sci. Technol. 2014, 48, 8706–8716.
69. Thomas, R.S.; Philbert, M.A.; Auerbach, S.S.; Wetmore, B.A.; Devito, M.J.; Cote, I.; Rowlands, J.C.; Whelan, M.P.; Hays, S.M.; Andersen, M.E. et al. Incorporating new technologies into toxicity testing and risk assessment: Moving from 21st century vision to a data-driven framework. Toxicol. Sci. 2013, 136, 4–18.
70. Papazisis, K.T.; Geromichalos, G.D.; Dimitriadis, K.A.; Kortsaris, A.H. Optimization of the sulforhodamine b colorimetric assay. J. Immunol. Methods 1997, 208, 151–158.